Announced
Financials
Sources
Tags
China
Pharmaceuticals
pharmaceutical solutions
Private
Cross Border
plasma medicines
Majority
Acquisition
Friendly
Pending
Single Bidder
Synopsis
Haier, a business conglomerate, agreed to acquire a 20% stake in Shanghai RAAS, a producer of blood products, from Grifols, a pharmaceutical and chemical manufacturer, for $1.8bn. "SRAAS is committed to the pursuit of safety, quality, and innovation, and we share the same vision of putting people at the center of everything we do and always striving for excellence. We look forward to working together with SRAAS and Grifols further to drive integration and innovation of the plasma value chain and contribute to the sustainable development of China’s healthcare industry,” Lixia Tan, Haier Vice Chairwoman.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.